A rheumatoid, short for rheumatoid arthritis (RA), is a chronic autoimmune disease in which the body’s immune system mistakenly attacks the lining of the joints, causing pain, swelling, and progressive damage. Unlike the wear-and-tear arthritis that develops with age, RA is driven by immune dysfunction and can strike at any age. About 18 million people worldwide live with it, and women are two to three times more likely to be affected than men.
How RA Differs From Regular Arthritis
Most people think of arthritis as something that happens when joints wear down over time. That’s osteoarthritis, and it’s primarily a mechanical problem caused by aging and physical stress on cartilage. Rheumatoid arthritis is fundamentally different. It’s a systemic autoimmune disease, meaning the immune system is actively attacking healthy tissue throughout the body, with the joints as the primary target.
The key biological difference is the severity of the immune response. In RA, specialized immune cells called T lymphocytes drive an aggressive inflammatory attack on the synovium, the thin membrane that lines each joint. This inflamed tissue grows abnormally into a mass called a pannus, which invades and erodes cartilage and bone directly. The pannus also releases chemical signals that activate bone-destroying cells and trigger further inflammation, creating a self-reinforcing cycle of damage.
Osteoarthritis tends to affect joints you’ve used hardest over a lifetime, like knees, hips, and the base of the thumb. RA typically shows up in smaller joints first, particularly the knuckles and wrists, and almost always affects both sides of the body symmetrically. If your right hand’s knuckles are swollen, the left hand’s knuckles probably are too.
Early Symptoms to Recognize
The hallmark symptom of RA is morning stiffness that lasts more than one hour and improves with movement. This is a crucial distinction. Stiff joints from osteoarthritis or sleeping in an odd position typically loosen within 15 to 30 minutes. With RA, you may spend the first hour or more of your day struggling to make a fist, grip a coffee mug, or bend your fingers fully.
Other early signs include joint swelling that feels warm or spongy to the touch, fatigue that seems disproportionate to your activity level, and low-grade fevers. The swelling reflects active inflammation inside the joint, not just fluid buildup. Many people also notice that symptoms come in waves, with flares lasting days or weeks before temporarily easing.
The speed of joint damage is a reason early recognition matters so much. Longitudinal studies using X-rays have shown that bone erosions appear in roughly half of untreated patients within just six months of disease onset. In some cases, erosions are detectable within weeks. This damage is permanent, which is why rheumatologists emphasize starting treatment as quickly as possible.
How RA Is Diagnosed
There’s no single test that confirms rheumatoid arthritis. Diagnosis relies on a combination of physical examination, blood work, and symptom history. The most widely used framework scores patients across four areas: the number and type of joints involved, blood markers of autoimmunity, markers of inflammation, and how long symptoms have lasted. A score of 6 or higher out of 10 supports a classification of RA.
Involvement of many small joints scores higher than involvement of a few large ones. Symptoms lasting six weeks or longer add to the score, as does the presence of elevated inflammation markers in blood tests.
Two blood tests play a central role. Rheumatoid factor (RF) and anti-CCP antibodies are both associated with RA, but neither is perfectly reliable on its own. Anti-CCP antibodies are present in only about 23% of patients in the earliest stages of the disease, rising to roughly 50% at the time of diagnosis and 53% to 70% within two years. Rheumatoid factor has a similar detection rate but is less specific to RA, since it can show up in other conditions and even in healthy older adults. About 20% to 30% of people with RA never test positive for either marker, a situation called seronegative RA. This is why a doctor’s clinical assessment of joint swelling remains the most important diagnostic step.
Effects Beyond the Joints
Because RA is a systemic disease, it doesn’t stop at the joints. The same inflammatory process can affect organs throughout the body, particularly in people with long-standing or poorly controlled disease.
- Lungs: Inflammation of the tissue surrounding the lungs (pleuritis) affects 5% to 10% of RA patients. A more serious complication, interstitial lung disease, occurs in roughly 8% to 12% of cases and involves scarring of lung tissue that can impair breathing over time.
- Heart: The most common cardiovascular complication is pericarditis, inflammation of the sac around the heart. RA also accelerates atherosclerosis, raising the risk of heart attack. Congestive heart failure is another association that often goes unrecognized.
- Eyes: At least 10% of people with RA develop dry eyes (keratoconjunctivitis sicca), often alongside dry mouth as part of a secondary condition called Sjögren’s syndrome. More serious eye inflammation, such as scleritis, can cause pain and vision changes.
These complications are more common in people who test positive for rheumatoid factor, and they underscore why controlling the disease early matters for more than just joint comfort.
How RA Is Treated
Treatment has changed dramatically over the past two decades. Current guidelines recommend starting disease-modifying therapy as soon as RA is diagnosed, rather than waiting to see how the disease progresses. The goal is remission, or at minimum, low disease activity that prevents joint destruction.
The first-line approach uses conventional disease-modifying drugs that calm the overactive immune system broadly. These are oral medications that have been used for decades, are relatively affordable, and have well-understood safety profiles. Most people start on one of these within weeks of diagnosis.
If the disease doesn’t respond adequately, the next step involves biologic therapies. These are protein-based drugs, usually given by injection or infusion, that target specific parts of the immune response. Some block a key inflammatory signal called TNF-alpha, others target particular immune cell types, and others interrupt the communication pathways that keep inflammation going. A newer class of oral drugs works by blocking signaling pathways inside immune cells, offering another option for people who don’t respond to earlier treatments.
The practical experience of treatment varies. Conventional drugs are daily or weekly pills. Biologics may require a self-administered injection every one to two weeks, or an infusion at a clinic every few weeks to months. Most people need regular blood work to monitor for side effects, and finding the right medication or combination can take several months of adjustment. But when treatment works, many people with RA achieve near-normal joint function and avoid the severe deformities that used to be considered inevitable.
Who Gets RA and Why
About 70% of people living with rheumatoid arthritis are women, a disparity that likely involves hormonal factors, though the exact mechanism remains unclear. RA most commonly begins between ages 30 and 60, but it can develop at any age, including in children (where it’s classified separately as juvenile idiopathic arthritis).
Genetics play a role. Certain inherited immune system genes significantly increase susceptibility. But genes alone don’t cause RA. Environmental triggers, particularly smoking, are strongly linked to disease onset and severity. Smoking is one of the few modifiable risk factors, and it also reduces the effectiveness of treatment once the disease develops. Infections, hormonal shifts, and even changes in gut bacteria have all been proposed as additional triggers in genetically susceptible people.